10-K: REMSleep Holdings 2025 Annual Report Analysis

REMSleep Holdings reports a significant net loss for 2025 while transitioning to its new DeltaWave CPAP product line.

Summary

• Reported a net loss of $3,020,300 for the fiscal year ended December 31, 2025, compared to a net loss of $1,077,997 in 2024.
• Revenue for 2025 was $16,721, down from $117,185 in 2024, reflecting the transition from selling CPAP machines to the new DeltaWave product.
• Operating expenses increased significantly to $2,771,786, driven largely by $2,269,500 in compensation expenses, including $2,160,000 in non-cash stock-based compensation.
• The company faces substantial doubt regarding its ability to continue as a going concern due to accumulated deficits and negative cash flows.
• Management successfully obtained FDA 510(k) clearance for the DeltaWave product in July 2024 and launched the product commercially in February 2026.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as highly speculative and distressed. While the company has achieved product milestones, the severe financial losses, going concern warning, and reliance on dilutive financing create extreme risk for investors.

Positives

• Received updated FDA 510(k) approval in January 2026, expanding the indicated use of the DeltaWave product.
• Secured PDAC coding approval, enabling Medicare reimbursement for the DeltaWave product line.
• Successfully launched the DeltaWave product commercially in February 2026.
• Reduced professional fees by 26.6% compared to the prior year.

Negatives

• Net loss widened to $3,020,300 in 2025 from $1,077,997 in 2024.
• Revenue declined sharply to $16,721 as the company discontinued its previous product line.
• Significant dilution risk due to ongoing reliance on convertible debt financing.
• Material weaknesses in internal controls over financial reporting remain, including lack of segregation of duties and absence of an independent audit committee.

Risks

• Substantial doubt regarding the company's ability to continue as a going concern.
• High dependence on external financing to fund operations and commercialization.
• Intense competition from much larger, better-capitalized companies like ResMed and Philips.
• Regulatory risks associated with FDA compliance and potential changes in healthcare reimbursement policies.
• Key person risk following the passing of founder and CEO Tom Wood in February 2026.

Future Outlook

The company expects to see sales of the DeltaWave product ramp up in Q2 2026. Management is focused on building a sales funnel, onboarding Durable Medical Equipment providers, and negotiating with hospital distributors. Future operations remain entirely dependent on securing adequate financing.

Management Comments

• Management believes the DeltaWave is designed to effectively address stubborn issues affecting patient compliance.
• The company expects that it will start to see sales ramping up in Q2 2026.
• Management acknowledges that substantial doubt exists regarding the company's ability to continue as a going concern.

Industry Context

StockSavvy.ai notes that the sleep apnea market is highly consolidated and dominated by large players like ResMed and Philips. REMSleep is attempting to enter this market with a niche product, but faces significant hurdles in scaling, distribution, and competing against established incumbents with vastly superior resources.

Comparison to Industry Standards

• The company is a micro-cap entity with negligible revenue compared to industry leaders like ResMed (45% market share) and Philips (30% market share).
• Unlike established competitors, the company lacks a robust sales and marketing infrastructure and relies on independent contractors.
• The company's reliance on convertible debt financing is common for early-stage OTC companies but contrasts with the stable capital structures of major medical device manufacturers.

Management Changes

Corporate Governance

Legal Proceedings

• None disclosed.

Related Party Transactions

• Employment agreement with Mr. Wood (former CEO) and compensation paid to him.
• Issuance of Series C preferred stock to Mr. Wood and Anita Michaels (COO) for services.
• Consulting agreement with Jonathan Lane (former CTO).
• Payments to the brother of the CEO for product development services.

Stakeholder Impact

• Shareholders face significant dilution risk from convertible debt conversions.
• Creditors are exposed to the company's going concern risk.
• Employees and contractors are dependent on the company's ability to secure ongoing financing.

Next Steps

• Ramp up sales of the DeltaWave product in Q2 2026.
• Continue negotiations with a key hospital distributor.
• Seek additional debt or equity financing to support operations.
• Potentially initiate formal clinical user preference trials later in 2026.

Key Dates

Recommendation

The company is in a distressed financial state with a significant net loss, declining revenue, and a going concern warning. The recent death of the founder and CEO adds significant leadership uncertainty. While the product has received regulatory approval, the path to profitability is highly uncertain and the reliance on dilutive financing makes this a high-risk investment.

Keywords

REMSleep Holdings, RMSL, DeltaWave, CPAP, sleep apnea, medical device, convertible debt, OTC